---
title: Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of Nonalcoholic Steatohepatitis
description: Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of NASH
---

[PathAI Resources ](https://www.pathai.com/resources)

# [Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of Nonalcoholic Steatohepatitis](https://www.pathai.com/resources/retrospective-ai-based-measurement-of-nash-histology-aim-nash-analysis-of-biopsies-from-phase-2-study-of-resmetirom-confirms-significant-treatment-induced-cha)

 Written by [Admin](https://www.pathai.com/resources/author/admin) | Jun 22, 2022 4:00:00 AM

## Study Background

- Biopsy-based endpoints are recommended for evaluating efficacy in nonalcoholic steatohepatitis (NASH) clinical trials due to slow progression of the disease. However, to date, no effective therapies have been identified.
- Manual histologic scoring of NASH features (lobular inflammation, ballooning, steatosis, fibrosis) is the current standard for assessing biopsies; however, manual scoring is subjective and prone to intra- and inter-rater variability, leading to only moderate-to-fair scoring reproducibility. Furthermore, manual scoring lacks the sensitivity to detect small histologic changes that may indicate treatment-induced clinical improvements.
- We hypothesize that improving the methods by which changes in NASH histology are measured may improve clinical trial outcomes. AI-assisted or -powered pathology may enhance the reproducibility and sensitivity of NASH histologic feature assessment and allow analyses of additional exploratory features with known critical relevance, such as portal inflammation.
- In the current retrospective analysis, we demonstrate the utility of an AI-based tool (AIM-NASH) for scoring NASH histology of liver biopsies from a Phase 2 trial of resmetirom (MGL-3196), a liver-targeted, oral, once-daily selective thyroid hormone receptor-β agonist in development for treatment of NASH with significant fibrosis.

[View full post](https://www.pathai.com/resources/retrospective-ai-based-measurement-of-nash-histology-aim-nash-analysis-of-biopsies-from-phase-2-study-of-resmetirom-confirms-significant-treatment-induced-cha)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Admin"
  },
  "dateModified" : "2025-08-06T19:39:13.976Z",
  "datePublished" : "2022-06-22T04:00:00Z",
  "headline" : "Retrospective AI-based Measurement of NASH Histology (AIM-NASH) Analysis of Biopsies From Phase 2 Study of Resmetirom Confirms Significant Treatment-induced Changes in Histologic Features of Nonalcoho",
  "image" : {
    "@type" : "ImageObject",
    "height" : 60,
    "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
    "width" : 60
  },
  "mainEntityOfPage" : "https://www.pathai.com/resources/retrospective-ai-based-measurement-of-nash-histology-aim-nash-analysis-of-biopsies-from-phase-2-study-of-resmetirom-confirms-significant-treatment-induced-cha",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "PathAI Resources"
  }
}
```